SCHEMBL3102160

SCHEMBL3102160

CC(C)OCCNC(=O)Nc1nc2cc(F)c(OC(C)c3c(Cl)ccc(F)c3Cl)cc2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 17/20 0.42
KDR P35968 5/20 0.40
ALK Q9UM73 1/20 0.40
FGFR2 P21802 2/20 0.39
AXL P30530 2/20 0.39
FLT3 P36888 2/20 0.39
MST1R Q04912 2/20 0.39
LCK P06239 2/20 0.39
ABL1 P00519 2/20 0.39
AURKA O14965 1/20 0.39
FYN P06241 1/20 0.39
YES1 P07947 1/20 0.39
EPHA2 P29317 1/20 0.39
LTK P29376 1/20 0.39
PTK6 Q13882 1/20 0.39
SRC P12931 2/20 0.39
KIT P10721 1/20 0.39
MAP4K2 Q12851 1/20 0.38
MAP3K1 Q13233 1/20 0.38
AAK1 Q2M2I8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104591 0.93 MET (0.42) METKDRALKFGFR2AXL
SCHEMBL3093416 0.92 MET (0.39) METKDRALKFGFR2AXL
SCHEMBL3110077 0.92 ABL1 (0.45) METKDRALKFGFR2AXL
SCHEMBL3104496 0.92 MET (0.43) METKDRALKFGFR2AXL
SCHEMBL3098297 0.92 MET (0.43) METKDRALKFGFR2AXL
SCHEMBL3097959 0.92 MET (0.43) METKDRALKFGFR2AXL
SCHEMBL3109366 0.92 ABL1 (0.45) METKDRALKFGFR2AXL
SCHEMBL3102583 0.91 MET (0.42) METKDRALKFGFR2AXL
SCHEMBL3650561 0.91 MET (0.42) METKDRALKFGFR2AXL
SCHEMBL3112125 0.90 MET (0.41) METKDRALKFGFR2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 MET 1/4885KDR 41/4885ALK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.